title: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.
abstract: The MAGE gene is selectively expressed in cancer tissues such as melanoma or gastrointestinal carcinomas, whereas no expression is observed in normal tissues except testis. There are several reports of successful induction of HLA class I-restricted antitumor CTLs using MAGE peptides, and some clinical trials with these immunogenic peptides were reported as effective for some patients with malignant melanoma. However, there are no similar studies in gastrointestinal carcinomas, which are important neoplasms. Autologous dendritic cells (DCs) were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A2 or A24). Patients were immunized with DC pulsed with MAGE-3 peptide every 3 weeks at four times. Twelve patients with advanced gastrointestinal carcinoma (six stomach, three esophagus, and three colon) were treated, and no toxic side effects were observed. Peptide-specific CTL responses after vaccination were observed in four of eight patients. Improvement in performance status was recognized in four patients. Tumor markers decreased in seven patients. In addition, minor tumor regressions evidenced by imaging studies were seen in three patients. These results suggested that DC vaccination with MAGE-3 peptide is a safe and promising approach in the treatment of gastrointestinal carcinomas.
authors.affiliation: Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Sadanaga
authors.forename: H
authors.initials: H
authors.lastname: Nagashima
authors.forename: K
authors.initials: K
authors.lastname: Mashino
authors.forename: K
authors.initials: K
authors.lastname: Tahara
authors.forename: H
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: M
authors.initials: M
authors.lastname: Ohta
authors.forename: T
authors.initials: T
authors.lastname: Fujie
authors.forename: F
authors.initials: F
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: K
authors.initials: K
authors.lastname: Takesako
authors.forename: T
authors.initials: T
authors.lastname: Akiyoshi
authors.forename: M
authors.initials: M
authors.lastname: Mori
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis; D018395:CA-19-9 Antigen / Q000032:analysis; D019496:Cancer Vaccines / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D007150:Immunohistochemistry; D016219:Immunotherapy, Adoptive; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D015843:Serpins; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D018395:CA-19-9 Antigen; D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D015843:Serpins; C051072:squamous cell carcinoma-related antigen